Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP)’s share price reached a new 52-week low during trading on Thursday . The stock traded as low as $0.34 and last traded at $0.35, with a volume of 2933800 shares traded. The stock had previously closed at $0.37.
OHRP has been the subject of several research reports. Roth Capital initiated coverage on shares of Ohr Pharmaceuticals in a research note on Monday, November 27th. They issued a “buy” rating and a $7.00 price target for the company. Zacks Investment Research downgraded shares of Ohr Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 20th. Finally, ValuEngine upgraded shares of Ohr Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, December 1st.
The firm has a market cap of $18.44, a PE ratio of -0.56 and a beta of 0.48.
Ohr Pharmaceuticals Company Profile
OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
Receive News & Ratings for Ohr Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.